BioAdvance News Portfolio News Relmada Therapeutics

Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels

By WebmasterOctober 2, 2018November 1st, 2024No Comments

Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels
Findings of REL-1017 Effect on BDNF Plasma Levels to be Presented at the Annual Meeting of the American College of Neuropsychopharmacology

See more here

Previous PostMelior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes
Next PostVenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133

Relmada Therapeutics to Present Clinical Data on the Effect of REL-1017 on BDNF Plasma Levels

SEARCH

TOPICS

ARCHIVES

RECENT POSTS

Previous PostMelior Pharmaceuticals Enrolls Last Subject in Phase 2b Study with Tolimidone for Type 2 Diabetes

Next PostVenatoRx Pharmaceuticals and Everest Medicines ll Limited Announce Exclusive License Agreement for cefepime/VNRX-5133